CVS Health’s latest quarter saw the company deliver revenue and profit above Wall Street’s expectations, but the market responded negatively. Management pointed to consistent gains in its core segments, driven by pharmacy strength and progress in Medicare margin recovery. CEO David Joyner highlighted the quarter as "another demonstration of disciplined execution," emphasizing ongoing improvement in the company’s medical benefit ratio and strong cash flow generation.
Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).
CVS Health (CVS) Q3 2026 highlights:
- Revenue $108.4 billion vs S&P analysts’ estimates of $104.2 billion (5.4% year-on-year growth, 4.1% beat)
- Adjusted EPS $2.09 vs S&P analysts’ estimates of $1.65 (26.6% beat)
- Adjusted operating income $4.19 billion vs analyst estimates of $3.60 billion (3.9% margin, 16.5% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $8.20 at the midpoint, a 2.5% increase
- Operating margin 3.3%, up from -3.1% in the same quarter last year
- Locations 8,926.4 at quarter end, down from 9,014 in the same quarter last year
- Same-store sales were flat year on year (14.3% in the same quarter last year)
- Market capitalization $104.1 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from CVS Health’s Q3 earnings call
- Lisa Gill (JPMorgan): asked about the timing and rationale for separating the company. CEO David Joyner explained the decision was made from a position of strength after progress in Medicare recovery and retail pharmacy growth.
- Justin Lake (Wolfe Research): questioned the impact of the split on capital deployment and leverage. CFO Brian Newman responded both new companies would retain investment-grade credit ratings and strong cash flow, with share repurchases expected to resume.
- Michael Cherny (Leerink Partners): inquired about possible dis-synergies from separating overlapping business functions. Joyner said integration benefits would be preserved through commercial agreements and that Health100 would serve as a connective platform.
- Elizabeth Anderson (Evercore ISI): asked about new opportunities for the retail stores post-split. Prem Shah, incoming CEO of CVS Pharmacy, highlighted the ability to expand healthcare services, leverage store footprint, and further invest in technology and workforce.
- Stephen Baxter (Wells Fargo): sought clarity on the potential operating cost dis-synergies. Newman stated that while some one-time and stranded costs are expected, they are manageable and offset by long-term value from the new structure.
Catalysts in upcoming quarters
In coming quarters, the StockStory analyst team will be watching (1) the progress and milestones toward the planned company separation, (2) ongoing improvement in Medicare margins and management of 340B program headwinds, and (3) adoption and consumer traction for the Health100 digital platform. We will also closely monitor specialty pharmacy growth and how both entities prepare for independent operations.
CVS Health currently trades at $81.22, down from $91.60 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
